“Body Contouring Devices and Procedures Market Report is set to have rapid growth due to the factors, such as quick adoption of technologically advanced products, high domestic income, and rise in demand for noninvasive procedures at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Body Contouring Devices and Procedures Market Forecast 2019-2029: By Device Type, By Procedure Type (Cellulite Treatment, Liposuction), By End Use, And Segment Forecasts

One of the major reason for increasing demand for body contouring devices and procedures is rising cases of obesity across the globe due to unhealthy lifestyle. The increased life expectancy resulting from the improved safety and efficacy of body contouring devices, besides their ease of use, cost-effective, and less painful has also resulted in the growth of the market. Moreover, initiatives, such as M&A and partnerships, undertaken by major companies for product research and distribution are also fuelling the market growth. The technological development in this segment will fuel its growth.

The market is divided into segments of non-invasive and minimally invasive which holds the major share of the market. This segment also witness massive R&D by the key players which has enhanced safety, short downtimes, and cost-effectiveness of these devices and the procedures.

The clinics and spa centres are the major players in this segment owing to technologically advanced devices and reduced risks of hospital-acquired infections.

Leading companies featured in the report include: Cynosure, Inc., Alma Lasers, Alleragan, Syneron Medical Ltd., Bausch Health Companies, Inc., Lumenis, Merz Pharma, Meridian, InMode Aesthetic Solutions, El.En. S.p.A. (Asclepion Laser Technologies GmbH).

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever